NEW YORK, NY — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is on track to dose the first patient in its planned global Phase 3 registrational trial in first line pancreatic cancer patients in...
Latest News
CAMBRIDGE, Mass. — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with...
NEW YORK, NY —Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of key data in an oral and four poster presentations, including one late-breaking poster, at the 41st Congress of the European Committee for Treatment...
At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years NEW YORK, NY — Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a...
ROYAL OAK, Mich. — IMMUNIS.AI, an immunogenomics company developing blood-based cancer surveillance technologies, today announced that results from a prostate cancer risk stratification study evaluating the company’s novel blood-based liquid biopsy platform were published in The Journal of Urology. The results validate the ability of the platform to accurately stratify...
JERUSALEM, Israel — Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients. The study demonstrated statistically significant efficacy as measured by change in the slope decline of ALSFRS-R. The drug was well tolerated, and the...
CULVER CITY, Calif. – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has administered its proprietary Natural Killer cells to more than 100 patients. The cells were administered as part of combination therapies in trials across multiple indications, including pancreatic, triple-negative breast, and Merkel Cell Carcinoma cancers....
CULVER CITY, Calif. – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the launch of the preclinical development of its liquid tumor pipeline with the publication of results from its Phase 1 study evaluating Anktiva™ (N-803), its IL-15 superagonist, in combination with Rituxan® (rituximab), an anti-CD20 monoclonal antibody...
CULVER CITY, Calif. — ImmunityBio, Inc. a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety portions of a clinical trial that is studying ImmunityBio’s investigational cancer vaccine of a tri-valent combination of antigens delivered by a second-generation Adenovirus vector (Tri-Ad5 CEA/MUC1/brachyury) together...
CULVER CITY, Calif. — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its investigational immune-boosting regimen including ANKTIVA® (nogapendekin alfa inbakicept-pmln) in this pilot study (NCT06061809). All five patients achieved 100% disease control with the regimen that combines...